Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
Fruquintinib has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of metastatic colorectal cancer. Eligibility requires that patients have either previously received, or are not suitable for, treatment with fluoropyrimidine-, oxaliplatin-,…
Read more
A new indication has been added to the Wegovy® (semaglutide) product information. Provisional approval has been granted for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis….
Read more
Durvalumab is an immune checkpoint inhibitor that targets programmed death-ligand 1 (PD-L1), enhancing T-cell activation and anti-tumour immune responses. A new indication has recently been added to its product information, alongside an expansion of…
Read more
The Australian Technical Advisory Group on Immunisation (ATAGI) has released its clinical advice for influenza vaccination in 2026. Annual vaccination continues to be recommended for all people six months of age and older. A…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for ravulizumab has been expanded to include generalised myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune disorder that affects postsynaptic acetylcholine receptors (AChR). Neuromuscular transmission is disrupted,…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for incobotulinumtoxinA (Xeomin®) has expanded to include chronic sialorrhea. Eligible patient groups include: Adults with Parkinson’s disease, atypical Parkinson’s, traumatic brain injury, or chronic sialorrhea following an acute…
Read more
